LAN NGUYEN: Open Payments
NPI 1326472002 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,376 in 127 payments from 17 companies in 2025. Trend: 2023 $1,332 · 2024 $1,464 · 2025 $2,376
Food & beverage: $2,297Education: $79
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 29 | $543 |
| Viatris Specialty LLC | 15 | $289 |
| GlaxoSmithKline, LLC. | 22 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $197 |
| Grifols USA, LLC | 7 | $175 |
| GENZYME CORPORATION | 9 | $169 |
| Regeneron Healthcare Solutions, Inc. | 9 | $149 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $143 |
| Verona Pharma, Inc. | 5 | $103 |
| SANOFI-AVENTIS U.S. LLC | 1 | $79 |
Products named: DUPIXENT, YUPELRI, GLASSIA, Prolastin-C Liquid, TEZSPIRE, NUCALA, FASENRA, BREZTRI.
Industry payments across AR — which companies pay providers there.
